NewcelX Collaborates with Eledon to Advance Diabetes Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Source: PRnewswire
- Collaborative Research Agreement: NewcelX has signed a collaborative research agreement with Eledon to integrate its lead product NCEL-101 with Eledon's anti-CD40L monoclonal antibody tegoprubart, aiming to advance a functional cure for Type 1 Diabetes, marking a significant advancement in diabetes treatment.
- Integration of Clinical Experience: Eledon's clinical experience with over 100 transplant patients will provide crucial clinical data and insights for the development of NCEL-101, potentially streamlining the regulatory pathway and accelerating the product's market entry.
- Enhanced Immune Modulation: The immune modulation component of NCEL-101 is designed to improve cell durability and graft survival, with expectations to match outcomes seen with donor human islets, thereby enhancing treatment efficacy and addressing market demand for functional insulin-producing cells.
- Strategic Milestone: NewcelX's Chief Scientific Officer stated that this collaboration not only enhances the company's clinical execution capabilities but also broadens partnerships with leaders in immune biology and transplant medicine, which is expected to accelerate clinical project advancement and increase visibility among investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NCEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NCEL
About NCEL
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
NewcelX Schedules Pre-IND Meeting with FDA to Advance Type 1 Diabetes Treatment
- Clinical Trial Milestone: NewcelX has submitted a Pre-IND briefing package to the FDA to advance NCEL-101 into First-In-Human clinical trials, marking a significant step in developing innovative treatments for type 1 diabetes, which could greatly enhance patient quality of life.
- Combination Therapy Approach: NCEL-101 is designed to be used in conjunction with Eledon's immunomodulatory agent, tegoprubart, aiming to achieve outcomes comparable to human islet transplantation, and if successful, it could provide a potential functional cure for type 1 diabetes, significantly impacting the market.
- Positive FDA Interaction: CEO Ronen Twito emphasized that the Pre-IND meeting represents a pivotal milestone in the company's commitment to curing type 1 diabetes, reflecting the FDA's support for innovations in this area, which may accelerate the clinical development process.
- Clinical Experience Support: The use of tegoprubart as an immunosuppressive agent in over 100 transplant recipients provides important safety and immunological insights that bolster the feasibility and market potential of advancing NCEL-101.
See More
NLS Pharmaceutics Reports FY 2025 Financial Results
- Financial Overview: NLS Pharmaceutics reported a GAAP EPS of -$2.16 for FY 2025, indicating ongoing financial losses that reflect the company's pressures and challenges in market competition.
- Cash Position: As of December 31, 2025, the company had $2.2 million in cash and cash equivalents, suggesting a tight liquidity situation that may impact future operational and investment decisions.
- Net Loss Breakdown: The net loss for 2025 was $8.3 million, including $5.7 million in non-cash accounting-related finance expenses primarily linked to the fair value remeasurement of convertible instruments, which are not expected to recur, potentially improving future financial conditions.
- Operating Cash Flow: The net cash used in operating activities was $2.8 million, reflecting increased investments in NCEL-101 development activities, which, while increasing short-term financial pressure, may enhance product development and market competitiveness in the long run.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Strategic Collaboration Highlight: NewcelX's partnership with Eledon Pharmaceuticals integrates its stem-cell-derived islet replacement platform with Eledon's immune modulation therapy, aiming to enhance treatment success rates and provide patients with more durable graft survival.
- Core Program Advancement: NCEL-101, NewcelX's flagship program, focuses on restoring insulin production through scalable cell replacement therapy, marking a strategic emphasis in diabetes treatment that is expected to significantly improve patient quality of life.
- Industry Presentation Plans: NewcelX plans to showcase its updated corporate presentation at the upcoming Swiss Biotech Conference, emphasizing its development vision for the diabetes program to attract more investment and collaboration opportunities.
- Forward-Looking Statements: The company notes in its press release that while the collaboration appears promising, it faces multiple uncertainties related to technology, market conditions, and regulatory approvals that could impact the progress of clinical trials and market acceptance of its products.
See More
NewcelX Announces Private Placement at 30% Premium, Stock Rises
- Private Placement Agreement: NewcelX announced a private placement at $2.75 per share, representing a 30% premium to the last closing price on March 31, 2026, indicating strong market confidence in the company's future.
- Shares and Warrants: The offering includes the sale of 490,907 common shares and warrants for 687,270 common shares at $3.025 each, expected to close around April 15, 2026, enhancing the company's capital structure.
- Clear Use of Proceeds: The company intends to use the net proceeds along with its previously announced $25 million equity line to advance NCEL-101, its lead program for Type 1 Diabetes, demonstrating a focus on core projects.
- Active Shareholder Participation: The offering includes participation from existing shareholders, reflecting investor recognition of the company's growth potential while providing funding support for operations and other development initiatives.
See More
NewcelX Secures Strong Financing to Advance Type 1 Diabetes Program
- Financing Details: NewcelX has entered into securities purchase agreements for a private placement at $2.75 per share, selling 490,907 common shares at a 30% premium to the last closing price, reflecting strong investor confidence in the company.
- Use of Proceeds: The net proceeds from this offering will be combined with a previously announced $25 million equity line to advance NCEL-101, NewcelX's lead program aimed at potentially curing Type 1 Diabetes, thereby enhancing the company's competitive position in the biopharmaceutical sector.
- Investor Participation: The offering includes participation from existing shareholders, reinforcing trust in the company's strategy and the potential of NCEL-101 to address significant unmet needs in Type 1 Diabetes, which is crucial for long-term growth.
- Compliance Statement: The securities are issued under Section 4(a)(2) of the Securities Act, ensuring compliance and reducing legal risks, which enhances investor confidence in the company's future developments.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
NewcelX Schedules Pre-IND Meeting with FDA to Advance Type 1 Diabetes Treatment
- Clinical Trial Milestone: NewcelX has submitted a Pre-IND briefing package to the FDA to advance NCEL-101 into First-In-Human clinical trials, marking a significant step in developing innovative treatments for type 1 diabetes, which could greatly enhance patient quality of life.
- Combination Therapy Approach: NCEL-101 is designed to be used in conjunction with Eledon's immunomodulatory agent, tegoprubart, aiming to achieve outcomes comparable to human islet transplantation, and if successful, it could provide a potential functional cure for type 1 diabetes, significantly impacting the market.
- Positive FDA Interaction: CEO Ronen Twito emphasized that the Pre-IND meeting represents a pivotal milestone in the company's commitment to curing type 1 diabetes, reflecting the FDA's support for innovations in this area, which may accelerate the clinical development process.
- Clinical Experience Support: The use of tegoprubart as an immunosuppressive agent in over 100 transplant recipients provides important safety and immunological insights that bolster the feasibility and market potential of advancing NCEL-101.
See More
NLS Pharmaceutics Reports FY 2025 Financial Results
- Financial Overview: NLS Pharmaceutics reported a GAAP EPS of -$2.16 for FY 2025, indicating ongoing financial losses that reflect the company's pressures and challenges in market competition.
- Cash Position: As of December 31, 2025, the company had $2.2 million in cash and cash equivalents, suggesting a tight liquidity situation that may impact future operational and investment decisions.
- Net Loss Breakdown: The net loss for 2025 was $8.3 million, including $5.7 million in non-cash accounting-related finance expenses primarily linked to the fair value remeasurement of convertible instruments, which are not expected to recur, potentially improving future financial conditions.
- Operating Cash Flow: The net cash used in operating activities was $2.8 million, reflecting increased investments in NCEL-101 development activities, which, while increasing short-term financial pressure, may enhance product development and market competitiveness in the long run.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Strategic Collaboration Highlight: NewcelX's partnership with Eledon Pharmaceuticals integrates its stem-cell-derived islet replacement platform with Eledon's immune modulation therapy, aiming to enhance treatment success rates and provide patients with more durable graft survival.
- Core Program Advancement: NCEL-101, NewcelX's flagship program, focuses on restoring insulin production through scalable cell replacement therapy, marking a strategic emphasis in diabetes treatment that is expected to significantly improve patient quality of life.
- Industry Presentation Plans: NewcelX plans to showcase its updated corporate presentation at the upcoming Swiss Biotech Conference, emphasizing its development vision for the diabetes program to attract more investment and collaboration opportunities.
- Forward-Looking Statements: The company notes in its press release that while the collaboration appears promising, it faces multiple uncertainties related to technology, market conditions, and regulatory approvals that could impact the progress of clinical trials and market acceptance of its products.
See More
NewcelX Announces Private Placement at 30% Premium, Stock Rises
- Private Placement Agreement: NewcelX announced a private placement at $2.75 per share, representing a 30% premium to the last closing price on March 31, 2026, indicating strong market confidence in the company's future.
- Shares and Warrants: The offering includes the sale of 490,907 common shares and warrants for 687,270 common shares at $3.025 each, expected to close around April 15, 2026, enhancing the company's capital structure.
- Clear Use of Proceeds: The company intends to use the net proceeds along with its previously announced $25 million equity line to advance NCEL-101, its lead program for Type 1 Diabetes, demonstrating a focus on core projects.
- Active Shareholder Participation: The offering includes participation from existing shareholders, reflecting investor recognition of the company's growth potential while providing funding support for operations and other development initiatives.
See More
NewcelX Secures Strong Financing to Advance Type 1 Diabetes Program
- Financing Details: NewcelX has entered into securities purchase agreements for a private placement at $2.75 per share, selling 490,907 common shares at a 30% premium to the last closing price, reflecting strong investor confidence in the company.
- Use of Proceeds: The net proceeds from this offering will be combined with a previously announced $25 million equity line to advance NCEL-101, NewcelX's lead program aimed at potentially curing Type 1 Diabetes, thereby enhancing the company's competitive position in the biopharmaceutical sector.
- Investor Participation: The offering includes participation from existing shareholders, reinforcing trust in the company's strategy and the potential of NCEL-101 to address significant unmet needs in Type 1 Diabetes, which is crucial for long-term growth.
- Compliance Statement: The securities are issued under Section 4(a)(2) of the Securities Act, ensuring compliance and reducing legal risks, which enhances investor confidence in the company's future developments.
See More
